KMB

Kimberly-Clark
D

KMB

Arincen66/100B

If you had invested in Kimberly-Clark ago, it would be worth $1,379 today, against $4,128 in SPY and $6,186 in QQQ.

ArincenArincen ScoreBeta

66/100

Six parts of the company, five checks each, from its own reported figures. A part scores the checks it passes out of 10; the score is their average out of 100.

Profitability10

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Cash6

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Valuation7.5

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Growth4

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Financial strength4

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Shareholders8

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Figures to FY2025; the price as of today.

Kimberly-Clark key facts

Style
Dividend stock · 9.7/10Growth 1.0 · Value 8.8 · Dividend 9.7
Day range
107.040 – 109.120
52-week range
92.420 – 116.820
Market capitalization
36.07B USD
P/E
10.92
PEG ratio
1.06
EPS
9.93
Div Yield
4.72%
EPS growth forecast (FY2026)
-1.7%
Volume
239,099
Beta
0.28
Sector
Consumer Defensive
Industry
Household & Personal Products
CEO
Michael D. Hsu
Employees
36K
IPO date
17 Mar 1980

Kimberly-Clark earnings

Latest results · Q3 FY2026
Reported EPS
1.70+3.03%
est. 1.65
Reported revenue
4.13B+0.18%
est. 4.13B
Next report · Q4 FY2026

Revenue

ReportedEstimate

EPS

ReportedEstimate
PeriodReport dateEPS estimateReported EPSSurpriseEPS growthRevenue estimateReported revenueSurpriseRevenue growth
Q3 FY20271.78——+5.00%4.22B——+2.15%
Q2 FY20271.91——+6.18%4.30B——+2.73%
Q1 FY20271.81——-8.10%4.24B——+1.90%
Q4 FY20261.66——-10.75%4.13B——+1.29%
Q3 FY20261.651.70+3.03%-6.59%4.13B4.13B+0.18%+0.02%
Q2 FY20262.011.80-10.45%-6.25%4.22B4.19B-0.84%+0.62%
Q1 FY20261.931.97+2.07%+2.07%4.09B4.16B+1.90%-13.99%
Q4 FY20251.811.86+2.76%+24.00%4.09B4.08B-0.33%-17.21%
Q3 FY20251.751.82+4.00%-0.55%4.09B4.13B+0.93%-16.54%
Q2 FY20251.671.92+14.97%-2.04%4.85B4.16B-14.14%-17.22%

Kimberly-Clark analyst forecast

12-month price target
114.20 USD
+5.31%

Analysts' 1-year price targets range from 105.00 to 120.00, with an average of 114.20.

Past year
1-year forecast
Strong sellStrong buy
Hold
11 ratings
Strong buy
0
Buy
3
Hold
7
Sell
1
Strong sell
0

12-month price target

Highest target120.00
Average target114.20
Lowest target105.00
Current price108.45

Kimberly-Clark valuation

Price to earnings ratio (TTM)
10.92
Forward P/E (FY2026)
14.64
Price to sales (TTM)
2.18
Price to book
11.73
EV / EBITDA (TTM)
13.10

Capital structure

Market capitalization
36.07B USD
+
Total debt
5.88B USD
−
Cash and short-term investments
1.87B USD
=
Enterprise value
40.07B USD

Valuation over time

P/EForward P/EForward P/E · EstimateEstimate
Fiscal yearP/EForward P/EP/SP/BEV/EBITDA
FY2027 (est.)14.67————
FY2026 (est.)14.6414.67———
Now (TTM)10.9214.672.1811.7313.10
FY202516.5913.631.9522.3712.20
FY202417.2917.522.2052.5712.83
FY202323.3220.592.0144.9615.70
FY202223.6920.592.2783.7315.97
FY202126.5725.432.4893.7917.44

Kimberly-Clark against its own history

Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.

Its peers: The Estée Lauder Companies, Church & Dwight Co., Colgate-Palmolive, The Clorox, e.l.f. Beauty, and Reynolds Consumer Products, the US Household & Personal Products companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.

  • P/E (today)Lowest in 5 years10.9
    10.927.6
  • Gross marginAbove its median35.6%
    30.8%35.8%
    Against its peers: 6 of 7Peers' median 52.4%
  • Operating marginAbove its median14.5%
    11.5%16.0%
    Against its peers: 4 of 7Peers' median 14.7%
  • Net marginAbove its median11.7%
    8.6%12.7%
    Against its peers: 2 of 7Peers' median 8.4%
  • Return on equityLowest in 5 years134.6%
    134.6%353.6%
    Against its peers: 3 of 7Peers' median 15.9%
  • Free cash flow marginAt its median9.5%
    8.9%13.6%
    Against its peers: 4 of 7Peers' median 10.2%
  • Revenue growthLowest in 5 years-14.2%
    -14.2%3.8%
    Against its peers: 7 of 7Peers' median 1.5%
  • EPS growthBelow its median-19.6%
    -22.1%44.9%
    Against its peers: 3 of 6Peers' median -25.1%
  • Debt to EBITDABelow its median2.21×
    1.99×2.68×
    Against its peers: 3 of 7Peers' median 3.80×
  • Current ratioLowest in 5 years0.75
    0.750.82
    Against its peers: 6 of 7Peers' median 1.14

Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.

Kimberly-Clark growth and profitability

Revenue (TTM)
16.57B USD
Net income (TTM)
3.30B USD
Gross margin
36.48%
Operating margin
11.75%
Net margin
19.93%

Revenue / Net income

Revenue Net income Net margin
PeriodRevenueGrowthNet incomeGrowthGross marginOperating marginNet marginEBITDAGrowth
FY202517.22B-14.17%2.02B-20.59%35.61%14.46%11.74%3.30B-17.14%
FY202420.06B-1.83%2.55B+44.27%35.80%16.00%12.69%3.98B+29.70%
FY202320.43B+1.27%1.76B-8.79%34.42%11.47%8.63%3.07B-9.15%
FY202220.18B+3.78%1.93B+6.62%30.83%13.29%9.59%3.38B+3.97%
FY202119.44B+1.57%1.81B-22.87%30.80%13.17%9.33%3.25B-18.38%

Kimberly-Clark revenue breakdown

By product

FY2025
Diapers: 41.5%Consumer tissue products: 24.8%Adult care products: 11.9%Away from Home Professional Products: 11.3%Feminine care products: 10.5%41.5%Diapers24.8%Consumer tissue products11.9%Adult care products11.3%Away from Home Professional Products10.5%Feminine care products
SegmentRevenueShare of revenueChange on the year
Diapers6.77B41.5%—
Consumer tissue products4.06B24.8%—
Adult care products1.95B11.9%—
Away from Home Professional Products1.84B11.3%—
Feminine care products1.71B10.5%—

By region

FY2025
100.0%United States
RegionRevenueShare of revenueChange on the year
United States10.10B100.0%-3.9%

How Kimberly-Clark makes its money

Revenue17.22B 100.0%
Cost of revenue11.09B 64.4%
Gross profit6.13B 35.6%
Selling and administration3.61B 21.0%
Other operating expenses27.00M 0.2%
Operating income2.49B 14.5%
Tax527.00M 3.1%
Net income2.02B 11.7%

FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.

Kimberly-Clark dividends

Annual dividend
5.12 USD
Dividend yield (indicated)
4.72%
Payout ratio
51.36%
Years of dividend growth
41
Frequency
Quarterly
Last payment
1.28 USD
Last ex-dividend date
4 Sept 2026
Last payment date
2 Oct 2026

Dividends per share

Year2025202420232022202120202019201820172016
Dividends per share5.004.844.704.624.494.244.093.973.833.64

Kimberly-Clark financial health

Cash and short-term investments
1.87B USD
Total debt
5.88B USD
Net cash
-4.01B USD
Free cash flow (TTM)
1.94B USD
Current ratio
0.89
Debt to equity
1.91
Piotroski score
7 / 9
Altman Z-score
3.72

Cash, debt and free cash flow

Cash and short-term investments Total debt Free cash flow
Fiscal yearCash and short-term investmentsTotal debtFree cash flow
FY2025688.00M7.30B1.64B
FY20241.02B7.92B2.51B
FY20231.09B8.11B2.78B
FY2022427.00M8.55B1.86B
FY2021270.00M8.70B1.72B

Kimberly-Clark ownership

Institutions
100.17%
Institutional holders
1,765 (+61)
Free float
99.62%

Who owns the shares

Institutions 100.0% Others 0.0%
As of 30 Jun 2026

Shares free to trade

Free float 331.31M shares ·99.6% Closely held 1.27M shares ·0.4%

Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.

Insider trading

QuarterPurchasesSalesShares acquiredShares disposed of
Q4 2026009.17K11.33K
Q3 2026006.25K8.89K
Q2 202603422.38K183.81K
Q1 20261142.31K14.30K

Shares outstanding

Basic shares Diluted shares Change in diluted shares
Fiscal yearBasic sharesDiluted sharesChange in diluted shares
FY2025333.10M333.10M-1.16%
FY2024337.00M337.00M-0.53%
FY2023338.58M338.80M+0.15%
FY2022337.40M338.30M-0.15%
FY2021337.30M338.80M-1.08%

Source: Financial Modeling Prep

Related Instruments

Title: Kimberly/Clark Corp

Sector: Consumer Defensive
Industry: Household & Personal Products
With more than half of its sales from personal care and another third from consumer tissue products, Kimberly-Clark is a leading manufacturer in the tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates in the professional segment, partnering with businesses to provide workplace safety and sanitation solutions. Kimberly-Clark generates just over half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America. It is slated to add Kenvue's consumer health portfolio to its mix in the second half of calendar year 2026.

Common questions about Kimberly-Clark stock

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.